Bailey CJ, Day C. Metformin: its botanical background. Pract Diabetes Int. 2004;21(3):115–7.

Article  Google Scholar 

Sterne J. Innovations in antidiabetics. NN dimethylamine guanyl guanidine [NNDG]. Maroc Med. 1957;36:1295–6.

Google Scholar 

Ra D. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. N Engl J Med. 1995;333:541–9.

Article  Google Scholar 

Campbell IW. Metformin: a 60-year odyssey with the journey still continuing–a personal commentary from Professor Ian Campbell. Curr Med Res Opin. 2022;38(1):55–8.

Article  PubMed  Google Scholar 

Petrie JR, Rossing PR, Campbell IW. Metformin and cardiorenal outcomes in diabetes: a reappraisal. Diabetes Obes Metab. 2020;22(6):904–15.

Article  CAS  PubMed  PubMed Central  Google Scholar 

LaMoia TE, Shulman GI. Cellular and molecular mechanisms of metformin action. Endocr Rev. 2021;42(1):77–96.

Article  PubMed  Google Scholar 

Rena G, Pearson ER, Sakamoto K. Molecular mechanism of action of metformin: old or new insights? Diabetologia. 2013;56:1898–906.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Misra P, Chakrabarti R. The role of AMP kinase in diabetes. Indian J Med Res. 2007;125(3):389–98.

CAS  PubMed  Google Scholar 

Foretz M, Guigas B, Viollet B. Understanding the glucoregulatory mechanisms of metformin in type 2 diabetes mellitus. Nat Rev Endocrinol. 2019;15(10):569–89.

Article  CAS  PubMed  Google Scholar 

Gerstein HC, Pare G, Hess S, Ford RJ, Sjaarda J, Raman K, McQueen M, Lee S, Haenel H, Steinberg GR. Growth differentiation factor 15 as a novel biomarker for metformin. Diabetes Care. 2017;40(2):280–3.

Article  CAS  PubMed  Google Scholar 

Proctor WR, Ming X, Bourdet D, Han TK, Everett RS, Thakker DR. Why does the intestine lack basolateral efflux transporters for cationic compounds? A provocative hypothesis. J Pharm Sci. 2016;105(2):484–96.

Article  CAS  PubMed  Google Scholar 

•• Tobar N, Rocha GZ, Santos A, Guadagnini D, Assalin HB, Camargo JA, Gonçalves AE, Pallis FR, Oliveira AG, Rocco SA, Neto RM. Metformin acts in the gut and induces gut-liver crosstalk. Proc Natl Acad Sci. 2023;120(4):e2211933120. https://doi.org/10.1073/pnas.2211933120. This study indicate that the first site of metformin action is the gut, and through gut-portal vein-liver crosstalk, it may have a role in the control of HGP, integrating the sites and the mechanisms of metformin action.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chang HS, Kim SJ, Kim YH. Association between colonic 18 F-FDG uptake and glycemic control in patients with diabetes mellitus. Nucl Med Mol Imaging. 2020;54:168–74.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Breining P, Jensen JB, Sundelin EI, Gormsen LC, Jakobsen S, Busk M, Rolighed L, Bross P, Fernandez-Guerra P, Markussen LK, Rasmussen NE. Metformin targets brown adipose tissue in vivo and reduces oxygen consumption in vitro. Diabetes Obes Metab. 2018;20(9):2264–73.

Article  CAS  PubMed  Google Scholar 

Bridges HR, Blaza JN, Yin Z, Chung I, Pollak MN, Hirst J. Structural basis of mammalian respiratory complex I inhibition by medicinal biguanides. Science. 2023;379(6630):351–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhang CS, Li M, Ma T, Zong Y, Cui J, Feng JW, Wu YQ, Lin SY, Lin SC. Metformin activates AMPK through the lysosomal pathway. Cell Metab. 2016;24(4):521–2.

Article  PubMed  Google Scholar 

Miller RA, Chu Q, Xie J, Foretz M, Viollet B, Birnbaum MJ. Biguanides suppress hepatic glucagon signaling by decreasing the production of cyclic AMP. Nature. 2013;494(7436):256–60.

Article  CAS  PubMed  PubMed Central  Google Scholar 

•• Foretz M, Guigas B, Viollet B. Metformin: update on mechanisms of action and repurposing potential. Nat Rev Endocrinolo. 2023;19(8):460–76. This Review highlights the latest advances in our understanding of the mechanisms of action of metformin and discuss potential emerging novel therapeutic uses like treatment of cancer, age-related diseases, inflammatory diseases and COVID-19.

Article  CAS  Google Scholar 

Garber AJ, Duncan TG, Goodman AM, Mills DJ, Rohlf JL. Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial. Am J Med. 1997;103(6):491–7.

Article  CAS  PubMed  Google Scholar 

Bennett WL, Maruthur NM, Singh S, Segal JB, Wilson LM, Chatterjee R, Marinopoulos SS, Puhan MA, Ranasinghe P, Block L, Nicholson WK. Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations. Ann Intern Med. 2011;154(9):602–13.

Article  PubMed  PubMed Central  Google Scholar 

Davidson MB, Peters AL. An overview of metformin in the treatment of type 2 diabetes mellitus. Am J Med. 1997;102(1):99–110.

Article  CAS  PubMed  Google Scholar 

Fujita Y, Inagaki N. Metformin: new preparations and nonglycemic benefits. Curr DiabRep. 2017;17:1.

CAS  Google Scholar 

Schwartz S, Fonseca V, Berner B, Cramer M, Chiang YK, Lewin A. Efficacy, tolerability, and safety of a novel once-daily extended-release metformin in patients with type 2 diabetes. Diabetes Care. 2006;29(4):759–64.

Article  CAS  PubMed  Google Scholar 

McCreight LJ, Bailey CJ, Pearson ER. Metformin and the gastrointestinal tract. Diabetologia. 2016;59(3):426–35.

Article  CAS  PubMed  PubMed Central  Google Scholar 

De Jager J, Kooy A, Lehert P, Wulffelé MG, Van der Kolk J, Bets D, Verburg J, Donker AJ, Stehouwer CD. Long-term treatment with metformin in patients with type 2 diabetes and risk of vitamin B-12 deficiency: randomized placebo-controlled trial. BMJ. 2010;20:340.

Google Scholar 

Aroda VR, Edelstein SL, Goldberg RB, Knowler WC, Marcovina SM, Orchard TJ, Bray GA, Schade DS, Temprosa MG, White NH, Crandall JP. Long-term metformin use and vitamin B12 deficiency in the diabetes prevention program outcomes study. J Clin Endocrinol Metab. 2016;101(4):1754–61.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Richy FF, Sabidó-Espin M, Guedes S, Corvino FA, Gottwald-Hostalek U. Incidence of lactic acidosis in patients with type 2 diabetes with and without renal impairment treated with metformin: a retrospective cohort study. Diabetes Care. 2014;37(8):2291–5.

Article  CAS  PubMed  Google Scholar 

Inzucchi SE, Lipska KJ, Mayo H, Bailey CJ, McGuire DK. Metformin in patients with type 2 diabetes and kidney disease: a systematic review. Jama. 2014;312(24):2668–75.

Article  PubMed  PubMed Central  Google Scholar 

Nadeau KJ, Chow K, Alam S, Lindquist K, Campbell S, McFann K, Klingensmith G, Walravens P. Effects of low dose metformin in adolescents with type I diabetes mellitus: a randomized, double-blinded placebo-controlled study. Pediatr Diabetes. 2015;16(3):196–203.

Article  CAS  PubMed  Google Scholar 

National Institute of Clinical Excellence. In: Type 1 diabetes in adults: diagnosis and management of type 1 diabetes. 2016. p. 29 Available from www.nice.org.uk/guidance/ng17?unlid=43059219201639184149. Accessed 22 May 2017.

Vella S, Buetow L, Royle P, Livingstone S, Colhoun HM, Petrie JR. The use of metformin in type 1 diabetes: a systematic review of efficacy. Diabetologia. 2010;53:809–20.

Article  CAS  PubMed  Google Scholar 

Lorenz MW, Polak JF, Kavousi M, Mathiesen EB, Völzke H, Tuomainen TP, Sander D, Plichart M, Catapano AL, Robertson CM, Kiechl S. Carotid intima-media thickness progression to predict cardiovascular events in the general population (the PROG-IMT collaborative project): a meta-analysis of individual participant data. Lancet. 2012;379(9831):2053–62.

Article  PubMed  PubMed Central  Google Scholar 

Libman IM, Miller KM, DiMeglio LA, Bethin KE, Katz ML, Shah A, Simmons JH, Haller MJ, Raman S, Tamborlane WV, Coffey JK. Effect of metformin added to insulin on glycemic control among overweight/obese adolescents with type 1 diabetes: a randomized clinical trial. JAMA. 2015;314(21):2241–50.

Article  CAS  PubMed  Google Scholar 

Petrie JR, Chaturvedi N, Ford I, Brouwers MC, Greenlaw N, Tillin T, Hramiak I, Hughes AD, Jenkins AJ, Klein BE, Klein R. Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 2017;5(8):597–609.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Polak JF, Szklo M, Kronmal RA, Burke GL, Shea S, Zavodni AE, O’Leary DH. The value of carotid artery plaque and intima-media thickness for incident cardiovascular disease: the multi-ethnic study of atherosclerosis. J Am Heart Assoc. 2013;2(2):e000087.

Article  PubMed  PubMed Central  Google Scholar 

Jablonski KA, McAteer JB, de Bakker PI, Franks PW, Pollin TI, Hanson RL, Saxena R, Fowler S, Shuldiner AR, Knowler WC, Altshuler D. Common variants in 40 genes assessed for diabetes incidence and response to metformin and lifestyle intervention in the diabetes prevention program. Diabetes. 2010;59(10):2672–81.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pau CT, Cheang KI, Modi BP, Kasippillai T, Keefe CC, Shulleeta M, Evans WS, Pal L, Strauss JF III, Nestler JE, Welt CK. The role of variants regulating metformin transport and action in women with polycystic ovary syndrome. Pharmacogenomics. 2016;17(16):1765–73.